Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Alliance Global Partners raised their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP opened at $0.15 on Wednesday. The stock has a market capitalization of $438,942.00, a PE ratio of 0.00 and a beta of 2.09. The business’s fifty day moving average price is $0.41 and its 200 day moving average price is $3.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. Tonix Pharmaceuticals has a 12-month low of $0.13 and a 12-month high of $29.76.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. The business had revenue of $2.21 million for the quarter, compared to the consensus estimate of $3.50 million. Equities research analysts forecast that Tonix Pharmaceuticals will post -12.37 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Armistice Capital LLC grew its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,770,000 shares of the company’s stock after acquiring an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned about 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.